At the Patient-Reported Outcome Session of CVCT Forum 2020, Dan Mark discussed the angina results of ISCHEMIA and ORBITA and the placebo effect. He explained that the most benefit was seen if you start off with a lot of angina in ISCHEMIA. He also brought up a major issue in quality of life assessment which is that patients can get used to their symptoms, restricting their activities to avoid getting the symptoms, and then saying they feel fine. Are they actually fine? And what if this means we can’t detect the benefit of a therapy in a trial because the patients start off too “well”?
I caught up with him after the debate to ask him more and also to find out how he got into research. Spoiler: the journey started with a Masters in Public Health after medical school.